Directors Gaby Longsworth, Ph.D., Uma Everett, Adam LaRock, Marsha Rose Gillentine, Ph.D., and Associate Ariana Randal authored "Chapter 17: Intellectual Property Considerations Related to Generic Products" in the Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Third Edition book recently published by ABA Book Publishing.
As noted by the publisher:
"ANDA patent litigations and strategies are complex, requiring that the patent professional can explain complex technical and legal issues to lay persons, both within the organization and to judges and juries. Now completely updated, this compendium provides lawyers with authoritative, in-depth information, tactics, and advice so that any pharmaceutical litigant wanting to increase market share, whether as an innovator or a generic, can plan early and be prepared to alter plans as new events occur.
All pharmaceutical companies, whether they are an innovator or a generic, must navigate the same complex legal and regulatory framework to bring a product to market and fend off competition. Now completely updated, Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Third Edition is an in-depth resource for learning about and planning for ANDA litigations and all the different avenues that pharmaceutical litigants could follow.
From the perspective of an innovator company, patents are vital to protect new drug products both to recoup the initial investment and for future investments. For the innovator and patent owner, the patentee must be aware of the risk to those intellectual property rights and be prepared for any patent challenge. Both entities can use Pre-ANDA Litigation as a resource to help formulate a strategy before patent litigation begins.
ANDA Patent litigations and strategies are complex and require the patent professional to be able to explain complex technical and legal issues to lay persons, both within the organization and to judges and juries. This compendium provides lawyers with invaluable and in-depth tactics and advice so that any pharmaceutical litigant wanting to increase market share, whether as an innovator or a generic, can plan early and be ready to alter plans as new events occur. Topics include:
- Coordinating new drug application (NDA) and patent portfolio strategy
- Preclinical and patent considerations
- Clinical trials and regulatory considerations
- Trademark (TM) and nonproprietary name considerations
- Acquiring and in-licensing pharmaceutical products
- Pre-litigation investigations and due diligence
- Market entry business considerations for generic companies"